![Peter Chin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Peter Chin
Chief Tech/Sci/R&D Officer at
DENALI THERAPEUTICS INC.
Net worth: 4 M $ as of 2026-05-30
Profile
Peter Chin is currently Chief Medical Officer & Head-Development at Denali Therapeutics, Inc. since 2025.
Education includes a doctorate from Geisel School of Medicine.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-04-09 | 204,402 ( 0.13% ) | 4 M $ | 2026-05-30 |
Peter Chin active positions
| Companies | Position | Start |
|---|---|---|
| DENALI THERAPEUTICS INC. | Chief Tech/Sci/R&D Officer | 2025-11-05 |
Training of Peter Chin
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
10
1st degree connections
2
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Denali Therapeutics, Inc.
 Denali Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops therapeutics for neurodegenerative diseases | Health Technology |
Geisel School of Medicine
 Geisel School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
- Stock Market
- Insiders
- Peter Chin
